Novel COVID-19 Vaccine NVX-CoV2515 Enhances Protection Against Omicron BA.1

Retrieved on: 2024-01-19 17:07:45

Tags for this article:

COVID-19 vaccination in the United States

RNA vaccines

Novavax COVID-19 vaccine

COVID-19 pandemic in South Africa

Pfizer-BioNTech COVID-19 vaccine

Moderna COVID-19 vaccine

SARS-CoV-2 Omicron variant

Click the tags to see associated articles and topics

Novel COVID-19 Vaccine NVX-CoV2515 Enhances Protection Against Omicron BA.1. View article details on HISWAI: https://www.hematologyadvisor.com/general-medicine/covid19-variant-specific-vaccine-elicits-superior-neutralizing-response-against-omicron/

Summary

The article describes the NVX-CoV2515 vaccine's stronger neutralizing response to the Omicron variant compared to the original NVX-CoV2373, maintaining a consistent safety profile following mRNA vaccines. Biotech developments and COVID-19 vaccine efficacy remain central themes.

Article found on: www.hematologyadvisor.com

View Original Article